<code id='843C5B489E'></code><style id='843C5B489E'></style>
    • <acronym id='843C5B489E'></acronym>
      <center id='843C5B489E'><center id='843C5B489E'><tfoot id='843C5B489E'></tfoot></center><abbr id='843C5B489E'><dir id='843C5B489E'><tfoot id='843C5B489E'></tfoot><noframes id='843C5B489E'>

    • <optgroup id='843C5B489E'><strike id='843C5B489E'><sup id='843C5B489E'></sup></strike><code id='843C5B489E'></code></optgroup>
        1. <b id='843C5B489E'><label id='843C5B489E'><select id='843C5B489E'><dt id='843C5B489E'><span id='843C5B489E'></span></dt></select></label></b><u id='843C5B489E'></u>
          <i id='843C5B489E'><strike id='843C5B489E'><tt id='843C5B489E'><pre id='843C5B489E'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:fashion    Page View:68271
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In